Employees: 780
Size Beijing Tong Ren Tang Chinese Medicine (3613.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $577M, the 714th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$5.43 on 18 Nov 2026.
Performance Over six months the shares fell 25.5%, against -23.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue fell 20.8% over the last twelve months (peer median +2.2%); the operating margin is 31.6% (peer median 4.7%).
Valuation It trades at 10.2× forward earnings against a peer median of 11.3× (4th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.4 points above its cost of capital (6.9% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.35B | HK$1.51B | HK$1.61B | HK$1.52B | HK$1.73B |
| Revenue growth | — | -6% | +6% | -12% | — |
| Gross profit | HK$847M | HK$836M | HK$990M | HK$976M | HK$1.09B |
| EBITDA | HK$526M | HK$572M | HK$660M | HK$699M | HK$877M |
| Net income | HK$361M | HK$397M | HK$500M | HK$540M | HK$646M |
| Free cash flow | HK$632M | HK$827M | -HK$201M | HK$502M | HK$519M |
| Capital expenditure | HK$27.4M | HK$41.2M | HK$43.2M | HK$21.9M | HK$38.5M |
| Total debt | n/a | HK$127M | HK$123M | HK$132M | HK$103M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3613.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.0% | -11.4% | 7th highest of 21 |
| 6-month return | -25.5% | -23.4% | 10th lowest of 21 |
| Distance from 52-week high | -42.8% | -44.0% | 9th highest of 21 |
| Revenue growth (TTM) | -20.8% | +2.2% | 5th lowest of 18 |
| Operating margin | 31.6% | 4.7% | highest of 17 |
| Forward P/E | 10.2× | 11.3× | 4th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -15.4% | -3.1% | least demanding of 10 |
| Growth delivered (Del g) | +2.8% | +11.1% | 3rd lowest of 10 |
| Hurdle (Req g minus delivered) | -18.3 pp | -9.9 pp | 3rd least demanding of 10 |
| ROIC minus cost of capital | +8.4 pp | -4.8 pp | 2nd highest of 15 |
| EV / EBITDA | 5.0× | 7.7× | 2nd cheapest of 5 |
| Net debt / EBITDA | -4.0× | 1.1× | 2nd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 10.2× | -15.4% | +2.8% |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | n/a | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | n/a | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 53.6× | n/a | n/a |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $583M | -20% | -6% | 5% | 26.8× | 20.9% | +21.9% |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | n/a | n/a | n/a |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | n/a | 50.4% | -12.3% |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 30.2× | 36.4% | +11.2% |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | n/a | n/a | n/a |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 9.0× | -5.8% | +4.1% |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 6.7× | -6.2% | +6.5% |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | n/a | n/a | n/a |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 11.3× | -3.1% | +12.6% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 54.0× | n/a | n/a |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 11.3× | -4.9% | +51.6% |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | n/a | -0.6% | -1.6% |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 9.6× | -12.3% | +11.1% |